JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Search

Denali Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

18.17 -2.94

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

18.16

Max

18.63

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.6M

-129M

Angestellte

503

EBITDA

8.9M

-125M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+98.2% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

11. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-93M

3.2B

Vorheriger Eröffnungskurs

21.11

Vorheriger Schlusskurs

18.17

Nachrichtenstimmung

By Acuity

10%

90%

7 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Denali Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Mai 2026, 23:43 UTC

Wichtige Nachrichtenereignisse

New Zealand's Unemployment Rate Falls in 1Q

5. Mai 2026, 23:20 UTC

Heiße Aktien

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5. Mai 2026, 21:48 UTC

Ergebnisse

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5. Mai 2026, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6. Mai 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5. Mai 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5. Mai 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5. Mai 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5. Mai 2026, 22:08 UTC

Ergebnisse

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5. Mai 2026, 22:07 UTC

Ergebnisse

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. Mai 2026, 21:48 UTC

Ergebnisse

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5. Mai 2026, 21:48 UTC

Ergebnisse

Pan American Silver 1Q Rev $1.2B >PAAS

5. Mai 2026, 21:42 UTC

Ergebnisse

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. Mai 2026, 21:38 UTC

Ergebnisse

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. Mai 2026, 21:30 UTC

Ergebnisse

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. Mai 2026, 21:29 UTC

Ergebnisse

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. Mai 2026, 21:26 UTC

Ergebnisse

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5. Mai 2026, 21:25 UTC

Ergebnisse

Alcon Inc. 1Q EPS 39c >ALC.EB

5. Mai 2026, 21:25 UTC

Ergebnisse

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5. Mai 2026, 21:24 UTC

Ergebnisse

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. Mai 2026, 21:18 UTC

Ergebnisse

Mistras Backs 2026 Rev $730M-$750M >MG

5. Mai 2026, 21:17 UTC

Ergebnisse

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5. Mai 2026, 21:15 UTC

Ergebnisse

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5. Mai 2026, 21:12 UTC

Ergebnisse

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5. Mai 2026, 21:11 UTC

Ergebnisse

SSR Mining 1Q Rev $581.8M >SSRM

5. Mai 2026, 21:10 UTC

Ergebnisse

SSR Mining 1Q Adj EPS $1.15 >SSRM

5. Mai 2026, 21:10 UTC

Ergebnisse

SSR Mining 1Q EPS $1.16 >SSRM

5. Mai 2026, 21:08 UTC

Ergebnisse

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. Mai 2026, 21:01 UTC

Ergebnisse

Intact Financial 1Q EPS C$4.12 >IFC.T

5. Mai 2026, 21:01 UTC

Heiße Aktien

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Peer-Vergleich

Kursveränderung

Denali Therapeutics Inc Prognose

Kursziel

By TipRanks

98.2% Vorteil

12-Monats-Prognose

Durchschnitt 36.27 USD  98.2%

Hoch 42 USD

Tief 30 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Denali Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

13

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

13.355 / 16.44Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

7 / 347 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat